Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups

Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups

Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory large B-cell lymphoma (LBCL) is scarce. We retrospectively collected data from patients with LBCL according to SCHOLAR-1 criteria treated wi...

Full description

Bibliographic Details
Main Authors: Mariana Bastos-Oreiro, Antonio Gutierrez, Juan Luís Reguera, Gloria Iacoboni, Lucía López-Corral, María José Terol, Valentín Ortíz-Maldonado, Jaime Sanz, Luisa Guerra-Dominguez, Rebeca Bailen, Alberto Mussetti, Pau Abrisqueta, Rafael Hernani, Hugo Luzardo, Juan-Manuel Sancho, Javier Delgado-Serrano, Antonio Salar, Carlos Grande, Leyre Bento, Sonia González de Villambrosía, Daniel García-Belmonte, Anna Sureda, Antonio Pérez-Martínez, Pere Barba, Mi Kwon, Alejandro Martín García-Sancho
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Immunology
Subjects:
refractory aggressive B cell lymphoma
CAR-T cell therapy
standard of care (SOC)
real world evidence (RWE)
scholar-1 criteria
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.855730/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.855730/full

Similar Items